• OECD approves application to initiate regulatory acceptance process for ecNGS technology, an improved method for mutagenesis testing.
• Duplex Sequencing ecNGS mutagenesis assays are poised to set benchmark for safety assessment in diverse sectors including pharmaceuticals, food, chemicals, and cosmetics as well as reduce the use of transgenic animals globally.
• This milestone underscores the power of TwinStrand’s patented Duplex Sequencing technology to advance the field of genetic toxicology, preventing carcinogenic products from entering the market, and ensuring the highest standards of safety in pharmaceutical and consumer products worldwide.

SEATTLE, April 24, 2024 /PRNewswire/ — TwinStrand Biosciences^®, the pioneer in Duplex Sequencing technology, which delivers accurate insights to researchers in applications ranging from genetic toxicology to residual cancer detection announces the successful acceptance of the standard project submission form (SPSF) by the Organization for Economic Cooperation and Development (OECD). This significant milestone will accelerate commencement of the global regulatory acceptance process for error-corrected Next Generation Sequencing (ecNGS) for mutagenesis testing.

“We are excited about this opportunity for ecNGS to become an approved tool for regulatory genotoxicity testing. By advancing our ability to evaluate mutation frequency and spectrums across any genome, these approaches can provide more precise and informative data for human health,” states Connie Chen from The Health and Environmental Sciences Institute’s Genetic Toxicology Technical Committee (HESI). 

Read full article on prnewswire.com